Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Lintzeris

Showing results (11-20 of 213) with videos related to

Pageof 22
Sort By:
Drug and Alcohol Review|May 11, 2022
Response to Steele and AchesonNicholas Lintzeris, Louisa Jansen, Victoria Hayes
JAMA Internal Medicine|January 7, 2020
Clinical Significance and Outcomes in Trial of Nabiximols for Treatment of Cannabis Dependence-ReplyNicholas Lintzeris, Jan Copeland, Raimondo Bruno
The Medical Journal of Australia|August 8, 2019
Regulatory and other responses to the pharmaceutical opioid problemGabrielle Campbell, Briony Larance, Nicholas Lintzeris
JAMA|March 8, 2017
Opioid Agonist Treatment for Patients With Dependence on Prescription OpioidsSuzanne Nielsen, Briony Larance, Nicholas Lintzeris
Drugs|August 23, 2018
Supervised Injectable Opioid Treatment for the Management of Opioid DependenceJames Bell, Vendula Belackova, Nicholas Lintzeris
The Medical Journal of Australia|March 4, 2024
The uptake of long-acting depot buprenorphine for treating opioid dependence in Australia, 2019-2022: longitudinal sales data analysisNicholas Lintzeris, Victoria Hayes, Adrian J Dunlop
The Medical Journal of Australia|July 17, 2021
Opioid prescribing in Australia: too much and not enoughAdrian J Dunlop, Buddhima Lokuge, Nicholas Lintzeris
The International Journal on Drug Policy|October 20, 2010
"Should I stay or should I go?" Coming off methadone and buprenorphine treatmentAdam R Winstock, Nicholas Lintzeris, Toby Lea
Drug and Alcohol Review|November 26, 2009
Why do patients report transferring between methadone and buprenorphine?Adam R Winstock, Nicholas Lintzeris, Toby Lea
Drug and Alcohol Review|January 22, 2021
Managing opioid withdrawal precipitated by buprenorphine with buprenorphineBridget Oakley, Hester Wilson, Victoria Hayes, et al.
Pageof 22

Showing results (11-20 of 213) with videos related to

Sort By:
Pageof 22
Drug and Alcohol Review|May 11, 2022
Response to Steele and AchesonNicholas Lintzeris, Louisa Jansen, Victoria Hayes
JAMA Internal Medicine|January 7, 2020
Clinical Significance and Outcomes in Trial of Nabiximols for Treatment of Cannabis Dependence-ReplyNicholas Lintzeris, Jan Copeland, Raimondo Bruno
The Medical Journal of Australia|August 8, 2019
Regulatory and other responses to the pharmaceutical opioid problemGabrielle Campbell, Briony Larance, Nicholas Lintzeris
JAMA|March 8, 2017
Opioid Agonist Treatment for Patients With Dependence on Prescription OpioidsSuzanne Nielsen, Briony Larance, Nicholas Lintzeris
Drugs|August 23, 2018
Supervised Injectable Opioid Treatment for the Management of Opioid DependenceJames Bell, Vendula Belackova, Nicholas Lintzeris
The Medical Journal of Australia|March 4, 2024
The uptake of long-acting depot buprenorphine for treating opioid dependence in Australia, 2019-2022: longitudinal sales data analysisNicholas Lintzeris, Victoria Hayes, Adrian J Dunlop
The Medical Journal of Australia|July 17, 2021
Opioid prescribing in Australia: too much and not enoughAdrian J Dunlop, Buddhima Lokuge, Nicholas Lintzeris
The International Journal on Drug Policy|October 20, 2010
"Should I stay or should I go?" Coming off methadone and buprenorphine treatmentAdam R Winstock, Nicholas Lintzeris, Toby Lea
Drug and Alcohol Review|November 26, 2009
Why do patients report transferring between methadone and buprenorphine?Adam R Winstock, Nicholas Lintzeris, Toby Lea
Drug and Alcohol Review|January 22, 2021
Managing opioid withdrawal precipitated by buprenorphine with buprenorphineBridget Oakley, Hester Wilson, Victoria Hayes, et al.
Pageof 22